Zymeworks BC Inc
Research Zymeworks BC Inc (ZYME) on Bullrun: market cap USD 2.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZYME
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.02B
- Financial periodQ2 2026
- RevenueUSD 4.59M
- Net income-USD 45.02M
- Free cash flow-USD 31.95M
Valuation Snapshot
latest market cap is USD 2.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 105.97M | -USD 81.13M | -USD 34.53M | n/a | -1.08 | USD 41.16M | USD 18.27M | USD 268.50M |
| FY2024 | USD 76.30M | -USD 122.70M | -USD 112.05M | n/a | -1.62 | USD 66.10M | USD 18.51M | USD 338.77M |
| FY2023 | USD 76.01M | -USD 118.67M | -USD 120.80M | n/a | -1.72 | USD 157.56M | USD 26.72M | USD 464.81M |
| FY2022 | USD 412.48M | USD 124.34M | USD 135.96M | n/a | 1.9 | USD 400.91M | USD 32.01M | USD 492.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.02B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.98B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.01B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 727.32M | 3.3 | n/a | n/a |
| 2022 | 2022-12-30 | USD 495.21M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 764.33M | n/a | n/a | n/a |
About Zymeworks BC Inc
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zymeworks BC Inc's market cap?
Zymeworks BC Inc's market capitalization is USD 2.02B.
What does Zymeworks BC Inc do?
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.